Skip to main content

Table 3 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on plasma concentration of sodium and potassium and plasma osmolality in a randomized, placebo-controlled, double-blind, crossover study of 19 healthy subjects

From: Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects

Periods Baseline L-NMMA Post infusion p (GLM-within)
0-90 min 90-120 min 120-150 min 150-180 min 180-210 min
p-sodium (mmol/l)
Placebo 140 ± 2 139 ± 1 139 ± 2** 139. ± 2 138 ± 2** 0.272
Tolvaptan 143 ± 2 143 ± 2 141 ± 3** 141 ± 2 141 ± 2*
P (Wilcoxon’s signed rank test) 0.001 0.001 0.002 0.001 0.001  
p- osm (mosm/kg)
Placebo 285 ± 3 285 ± 4 283 ± 4** 284 ± 4** 283 ± 4*** 0.352
Tolvaptan 291 ± 3 291 ± 3 291 ± 3 291 ± 3 290 ± 3
p (GLM between) <0.0001
p (paired t-test) <0.001 <0.001 <0.001 <0.001 <0.001  
p-potassium (mmol/l)
Placebo 3.8 ± 0.2 3.8 ± 0.3 3.9 ± 0.3 3.9 ± 0.2 3.8 ± 0.1 0.325
Tolvaptan 3.9 ± 0.2 3.9 ± 0.2 4.0 ± 0.2 4.0 ± 0.1 4.0 ± 0.1
p (Wilcoxon’s signed rank test) 0.028 0.117 0.272 0.929 0.430  
  1. Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subjects factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during infusion period 90–150 min, and at baseline vs post infusion period 150 – 210 min. *p < 0.05; **p < 0.001;***p < 0.0001.